The American Cancer Society, in partnership with Winship Cancer Institute of Emory University will partner on a project that aims to significantly accelerate cancer research and improve patient outcomes.
FDA approved Tafinlar (dabrafenib) with Mekinist (trametinib) for pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both drugs suitable for patients who cannot swallow pills.
Prelude Therapeutics Inc. formed a clinical trial collaboration with BeiGene for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, in hematologic malignancies.
FDA has approved an expanded indication for Eli Lilly and Company’s Verzenio (abemaciclib), in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at a high risk of recurrence.
FDA approved Roche’s VENTANA PD-L1 (SP263) assay as a companion diagnostic to identify non-small cell lung cancer patients eligible for treatment with Libtayo (cemiplimab), based on the results of the Phase III EMPOWER-Lung study.
FDA approved a single-dose, prefilled autoinjector presentation of Udenyca (pegfilgrastim-cbqv), a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia. The Udenyca autoinjector has a streamlined, easy-to-use design for use in both in-office and at-home settings of care.
FDA published updates to the mammography regulations to, among other things, require mammography facilities to notify patients about the density of their breasts, strengthen the FDA’s oversight and enforcement of facilities and help interpreting physicians better categorize and assess mammograms.
Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, and Foundation Medicine, have entered into a value-based agreement to make FoundationOne®CDx and FoundationOne®Liquid CDx, FDA-approved comprehensive genomic profiling tests, available to Point32Health members with advanced cancer, including Medicaid members.
C2i Genomics entered a collaboration agreement March 2 with Riken Genesis Co., Ltd. to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.
HRA Pharma Rare Diseases, a business of Perrigo Company, signed a partnership with Celnova Pharma, to ensure that the products developed by HRA Pharma Rare Diseases can be successfully registered and launched across Argentina, Chile, and Peru.
